Abstract
Introduction

Pioglitazone is one pharmacological ligand for PPARγ and it has been shown to increase insulin sensitivity in patients with diabetes (1). The action of the ligand is initiated through binding to its nuclear receptors and gene activation (2). In addition to the increase in insulin sensitivity, a variety of pharmacological effects of the ligand have been reported. The PPARγ ligand prevents cancer formation, atherosclerosis, cytokine-induced inflammation, and non-alcoholic steatohepatitis (NASH)
, although the precise molecular mechanisms of these effects are unknown (3, 4) . Cholangiocarcinoma is a predominantly fatal cancer, which can be difficult to treat (5 i g . 1 a . S e r u m c o n c e n t r a t i o n s o f a l a n i n e a mi n o t r a n s f e r a s e ( AL T ) , a s p a r a t e a mi n o t r a n s f e r a s e ( AS T ) , γ -g l u t a my l t r a n s p e pt i d a s e ( γ GT P ) a n d a l k a l i n e p h o s p h a t a s e ( AL P ) f r o m Ma r c h 2 0 0 3 t h r o u g h S e p t e mb e r 2 0 0 4 a r e s h o wn i n t h e u p p e r p a n e l . T h e Hb A1 c a n d s e r u m c o n c e n t r a t i o n o f CA1 9 -9 a r e s h o wn i n t h e l o we r p a n e l . 
F i g . 1 b . T h e s e r u m c o n c e n t r a t i o n s o f a l a n i n e a mi n o t r a n s f er a s e ( AL T ) , a s p a r a t e a mi n o t r a n s f e r a s e ( AS T ) , γ -g l u t a my lt r a n s p e p t i d a s e ( γ GT P ) a n d a l k a l i n e p h o s p h a t a s e ( AL P ) f r o m S e p t e mb e r 2 0 0 4 t h r o u g h Au g u s t 2 0 0 5 a r e s h o wn i n t h e u p p e r
p a n e l . T h e Hb A1 c a n d s e r u m c o n c e n t r a t i o n o f CA1 9 -9 a r e s h o wn i n t h e l o we r p a n e l . (Fig. 2a, b) (Fig. 2c) Autopsy showed that the main cause of death was obstructive jaundice due to intrahepatic highly differentiated cholangiocarcinoma at the hilum of the liver (Fig. 3) . Components of multicystic intraductal adenoma/ adenocarcinoma were seen frequently, suggesting that invasive carcinoma had arisen from bile duct cystadenocarcinoma. The cancer cells were immunohistochemically positive for anti-CA19-9 anti-
F i g . 2 . MRI s i n J u l y 2 0 0 3 ( a ) , Ma r c h 2 0 0 4 ( b ) , a n d Ma r c h 2 0 0 5 ( c ) , s h o we d t h e t u mo r i n t h e l i v e r . T h e r e we r e n o r e ma r k a b l e c h a n g e s i n t u mo r s i z e b e t we e n ( a ) a n d ( b ) . Ov e r t p r o g r e s s i o n c a n b e s e e n i n ( c ) .
body. There was no distant metastasis except for metastasis in the proximal lymph nodes. There was no evidence of NASH.
Discussion
At the first screening, tumor was identified in the liver. As markers of cholangiohepatic injury, the hepatic enzyme concentrations were elevated with an increase in CA19-9 concentration (7) . These (12) . Thiazolidinediones inhibit growth and produce terminal differentiation of human tumor cells (13) . Recently, it was reported that pioglitazone could suppress proliferation and induce apoptosis in cholangiocarcinoma cell lines (14) . However, two studies showed that PPARγ activator promoted colon tumor and polyp development in mice (15, 16 concentration of CA19-9 has been reported in a case of biliary obstruction (22) . Thus, we speculate that the re-elevation may have mainly been due to mechanical obstruction of the bile duct by the tumor, or that the agent itself promoted tumor progression during the terminal stages.
In conclusion, the PPARγ ligand improved the diabetes but also suppressed the hepatitis along with the malignant tumors. We recommend thiazolidinediones to improve diabetic condition and tumor-induced hepatitis, unless serious side effects develop.
